ClinicalTrials.gg

Program

olatorepatide

Also written as “Olatorepatide”, “HS-20094” and “HS-20094 Injection”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hidradenitis Suppurativa · Overweight, led by 2 companies.

Furthest: phase 3, since Feb 18, 202512 company-led studies, 7 open or runningLicense: Hansoh → Regeneron, Jun 2025Next primary completion: Mar 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group83 open or runningphase 3since Feb 18, 2025Oct 29, 2021Mar 30, 2027phase 3 · NCT07156500
Regeneron Pharmaceuticals44 open or runningphase 3since Oct 19, 2026Feb 18, 2026Jan 21, 2028phase 2 · NCT07685808
  • Named in Hansoh Pharmaceutical Group’s own pipeline as Olatorepatide (HS-20094), phase 4, as of Aug 26, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2021First study: phase 1 study in Diabetes Mellitus, Type 2New to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT05116410 · 68 enrolled · China
  2. May 25, 2023Phase 2 study in Diabetes Mellitus, Type 2Hansoh Pharmaceutical Group · NCT06118008 · 54 enrolled · China
  3. Oct 17, 2023Phase 2 study in OverweightHansoh Pharmaceutical Group · NCT06118021 · 200 enrolled · China
  4. Feb 18, 2025Phase 3 study in OverweightHansoh Pharmaceutical Group · NCT06839664 · 604 enrolled · China
  5. Feb 25, 2025Phase 2 study in Diabetes Mellitus, Type 2Hansoh Pharmaceutical Group · NCT06901648 · 275 enrolled · China
  6. Jun 2, 2025Phase 1 study in OverweightHansoh Pharmaceutical Group · NCT07057674 · 144 planned · China
  7. Aug 28, 20252 phase 3 studies in Diabetes Mellitus, Type 2Hansoh Pharmaceutical Group · NCT07156539, NCT07156500
  8. Feb 18, 2026Regeneron Pharmaceuticals's first study: phase 2 study in OverweightNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT07431086 · 120 enrolled · United States
  9. Jun 29, 2026Phase 2 study in OverweightRegeneron Pharmaceuticals · NCT07685808 · 360 planned · United States
  10. Sep 15, 2026Phase 2 study in Hidradenitis SuppurativaRegeneron Pharmaceuticals · NCT07830329 · 300 planned · United States
  11. Oct 19, 2026Phase 3 study in OverweightPhase 3 reachedRegeneron Pharmaceuticals · NCT07896265 · 3,000 planned

Ahead

  1. Nov 13, 2026Primary completion: phase 2 study in OverweightRegeneron Pharmaceuticals · NCT07431086
  2. Mar 30, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Hansoh Pharmaceutical Group · NCT07156539
  3. Mar 30, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Hansoh Pharmaceutical Group · NCT07156500
  4. Jan 21, 2028Primary completion: phase 2 study in OverweightRegeneron Pharmaceuticals · NCT07685808

TargetBeta

“A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity Without Diabetes (RISE-1)”study text, read by Claude · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
TirzepatideruleEli Lillyphase 472
retatrutideruleEli Lillyphase 333
UBT251The United Laboratories Internationalphase 312
enicepatideHoffmann-La Rochephase 310
VK2735ruleViking Therapeuticsphase 38
NNC0519-0130Novo Nordiskphase 211
BI 3034701Boehringer Ingelheimphase 26
HRS-4729Jiangsu HengRui Medicinephase 25
NA-931rulebiomed-industries-incphase 23

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07896265Overweight3Not yet recruitingRegeneron PharmaceuticalsDec 19, 20283,000
NCT07830329Hidradenitis Suppurativa · United States2RecruitingRegeneron PharmaceuticalsNov 24, 2028300
NCT07685808Overweight · United States2RecruitingRegeneron PharmaceuticalsJan 21, 2028360
NCT07431086Overweight · United States2Active, not recruitingRegeneron PharmaceuticalsNov 13, 2026120
NCT07156539Diabetes Mellitus, Type 2 · China3Not yet recruitingHansoh Pharmaceutical GroupMar 30, 2027546
NCT07156500Diabetes Mellitus, Type 2 · China3Not yet recruitingHansoh Pharmaceutical GroupMar 30, 2027204
NCT07057674Overweight · China1RecruitingHansoh Pharmaceutical GroupFeb 4, 2026144
NCT06901648Diabetes Mellitus, Type 2 · China2CompletedHansoh Pharmaceutical GroupMar 7, 2025275
NCT06839664Overweight · China3CompletedHansoh Pharmaceutical GroupJan 4, 2026604
NCT06118021Overweight · China2CompletedHansoh Pharmaceutical GroupAug 13, 2024200
NCT06118008Diabetes Mellitus, Type 2 · China2CompletedHansoh Pharmaceutical GroupJan 4, 202454
NCT05116410Diabetes Mellitus, Type 2 · China1UNKNOWNHansoh Pharmaceutical GroupOct 31, 202268

How it is read

Names in the registry

  • “Olatorepatide”, 4 entries
  • “HS-20094”, 3 entries
  • “HS-20094 Injection”, 3 entries
  • “HS-20094 injection”, 1 entry
  • “HS-20094 5mg”, 1 entry

Codes read as this program: HS20094.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.